All patients
corticosteroids: no corticosteroids: yes critical disease severe disease
Immunosuppressants drugs in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Amra, 2021 0.47 [0.12; 1.93]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.02 [0.62; 1.68]
MARIPOSA, 2021 1.43 [0.42; 4.87]
NCT04377750 (HMO-0224-20), 0 0.48 [0.15; 1.55]
Rashad, 2021 0.35 [0.17; 0.74]
Rashad, 2021 2.86 [1.36; 6.01]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
Talaschian, 2021 1.56 [0.34; 7.13]
Veiga, 2021 2.70 [0.92; 7.92]
0.88 [0.60 ; 1.29 ] Amra, 2021, CORIMUNO-TOCI-ICU (Group 2), 2020, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, MARIPOSA, 2021, NCT04377750 (HMO-0224-20), 0, Rashad, 2021, Rashad, 2021, Rosas (REMDACTA), 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Talaschian, 2021, Veiga, 2021 13 57% 1,961 moderate low deathsdetailed results Cao, 2020 0.15 [0.01; 3.29]
CORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
DEVENT, 0 0.47 [0.22; 1.00]
Hamed, 2021 1.83 [0.16; 21.66]
Kumar, 2021 0.06 [0.00; 1.35]
Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12]
Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50]
NCT04377750 (HMO-0224-20), 0 0.48 [0.15; 1.55]
Rashad, 2021 2.16 [1.14; 4.09]
Rashad, 2021 0.46 [0.24; 0.88]
REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95]
REMAP-CAP sarilumab, 2021 0.51 [0.25; 1.07]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
sarilumab phase 2 high dose, 0 0.78 [0.34; 1.80]
sarimulab phase 2 low dose, 0 1.51 [0.69; 3.32]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
Talaschian, 2021 1.25 [0.30; 5.14]
Veiga, 2021 2.70 [0.92; 7.92]
0.84 [0.66 ; 1.06 ] Cao, 2020, CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, DEVENT, 0, Hamed, 2021, Kumar, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, NCT04377750 (HMO-0224-20), 0, Rashad, 2021, Rashad, 2021, REMAP-CAP (tocilizumab), 2021, REMAP-CAP sarilumab, 2021, Rosas (REMDACTA), 2021, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Talaschian, 2021, Veiga, 2021 22 42% 4,040 moderate low deaths (time to event analysis only)detailed results COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
Rashad, 2021 2.16 [1.14; 4.09]
Rashad, 2021 0.46 [0.24; 0.88]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Talaschian, 2021 1.25 [0.30; 5.14]
1.04 [0.66 ; 1.65 ] COVACTA (Rosas), 2020, Rashad, 2021, Rashad, 2021, Rosas (REMDACTA), 2021, Talaschian, 2021 5 66% 1,430 moderate not evaluable clinical deteriorationdetailed results Cao, 2020 0.11 [0.01; 2.21]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20]
0.48 [0.20 ; 1.20 ] Cao, 2020, CORIMUNO-TOCI-1 (Group 1), 2020 2 6% 171 moderate not evaluable clinical improvementdetailed results Cao, 2020 1.67 [0.84; 3.33]
COV-BARRIER (critically ill), 2022 2.87 [1.12; 7.36]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15]
REMAP-CAP sarilumab, 2021 1.76 [1.12; 2.78]
sarilumab phase 2 high dose, 0 2.09 [1.00; 4.36]
sarimulab phase 2 low dose, 0 1.51 [0.73; 3.11]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
1.46 [1.22 ; 1.75 ] Cao, 2020, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, REMAP-CAP (tocilizumab), 2021, REMAP-CAP sarilumab, 2021, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 10 16% 2,328 moderate low clinical improvement (14-day)detailed results Cao, 2020 2.00 [0.58; 6.94]
COV-BARRIER (critically ill), 2022 1.97 [0.95; 4.09]
REMAP-CAP sarilumab, 2021 1.86 [1.20; 2.87]
1.90 [1.33 ; 2.71 ] Cao, 2020, COV-BARRIER (critically ill), 2022, REMAP-CAP sarilumab, 2021 3 0% 592 moderate not evaluable clinical improvement (21-day)detailed results Cao, 2020 1.50 [0.22; 10.08]
1.50 [0.22 ; 10.08 ] Cao, 2020 1 0% 41 NA not evaluable clinical improvement (28-day)detailed results COV-BARRIER (critically ill), 2022 1.82 [0.87; 3.81]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
1.33 [0.95 ; 1.87 ] COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 4 0% 564 moderate not evaluable clinical improvement (7-day)detailed results Cao, 2020 2.38 [0.38; 14.70]
2.38 [0.38 ; 14.70 ] Cao, 2020 1 0% 41 NA not evaluable clinical improvement (time to event analysis only)detailed results Cao, 2020 1.67 [0.84; 3.33]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54]
1.13 [0.92 ; 1.39 ] Cao, 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021 3 0% 548 moderate not evaluable death or ventilationdetailed results CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31]
Rosas (REMDACTA), 2021 0.98 [0.72; 1.34]
sarilumab phase 2 high dose, 0 0.39 [0.18; 0.82]
sarimulab phase 2 low dose, 0 0.70 [0.34; 1.44]
Veiga, 2021 1.54 [0.65; 3.63]
0.77 [0.51 ; 1.16 ] CORIMUNO-TOCI-1 (Group 1), 2020, Rosas (REMDACTA), 2021, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Veiga, 2021 5 50% 1,179 moderate not evaluable hospital dischargedetailed results MARIPOSA, 2021 0.88 [0.55; 1.40]
Rosas (REMDACTA), 2021 0.97 [0.79; 1.20]
0.95 [0.79 ; 1.16 ] MARIPOSA, 2021, Rosas (REMDACTA), 2021 2 0% 649 moderate not evaluable mechanical ventilationdetailed results COVACTA (Rosas), 2020 0.67 [0.39; 1.14]
Hamed, 2021 3.15 [0.57; 17.48]
MARIPOSA, 2021 0.88 [0.37; 2.10]
sarilumab phase 2 high dose, 0 0.27 [0.10; 0.71]
sarimulab phase 2 low dose, 0 0.28 [0.11; 0.73]
Singh (TD-0903 1mg), 2021 0.09 [0.00; 2.48]
Singh (TD-0903 3mg), 2021 0.08 [0.00; 2.07]
0.52 [0.28 ; 0.96 ] COVACTA (Rosas), 2020, Hamed, 2021, MARIPOSA, 2021, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 7 50% 714 moderate not evaluable radiologic improvement (14-day)detailed results Cao, 2020 5.54 [1.01; 30.50]
5.54 [1.01 ; 30.50 ] Cao, 2020 1 0% 41 NA not evaluable ICU admissiondetailed results COVACTA (Rosas), 2020 0.48 [0.25; 0.94]
Hamed, 2021 3.15 [0.57; 17.48]
1.04 [0.17 ; 6.33 ] COVACTA (Rosas), 2020, Hamed, 2021 2 75% 240 moderate not evaluable off oxygenationdetailed results sarilumab phase 2 high dose, 0 1.99 [0.95; 4.15]
sarimulab phase 2 low dose, 0 1.07 [0.52; 2.21]
1.46 [0.79 ; 2.68 ] sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0 2 28% 270 serious not evaluable recoverydetailed results COV-BARRIER (critically ill), 2022 1.57 [0.77; 3.20]
Talaschian, 2021 0.64 [0.14; 2.92]
1.30 [0.64 ; 2.66 ] COV-BARRIER (critically ill), 2022, Talaschian, 2021 2 9% 137 low not evaluable related AE (TRAE)detailed results Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 0.38 [0.01; 13.93]
1.26 [0.14 ; 11.07 ] Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 2 0% 25 moderate not evaluable serious adverse eventsdetailed results Cao, 2020 0.11 [0.01; 2.21]
COVACTA (Rosas), 2020 0.81 [0.54; 1.22]
Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12]
Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51]
Rosas (REMDACTA), 2021 0.83 [0.59; 1.18]
Talaschian, 2021 7.93 [0.37; 171.38]
Veiga, 2021 1.66 [0.60; 4.59]
0.99 [0.75 ; 1.32 ] Cao, 2020, COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Rosas (REMDACTA), 2021, Talaschian, 2021, Veiga, 2021 7 25% 1,788 moderate not evaluable adverse eventsdetailed results Cao, 2020 1.60 [0.38; 6.81]
COVACTA (Rosas), 2020 0.87 [0.52; 1.45]
Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69]
Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27]
Rosas (REMDACTA), 2021 1.32 [0.92; 1.89]
Singh (TD-0903 1mg), 2021 0.45 [0.01; 16.71]
Singh (TD-0903 3mg), 2021 0.04 [0.00; 1.01]
Veiga, 2021 1.65 [0.81; 3.37]
1.16 [0.91 ; 1.49 ] Cao, 2020, COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Rosas (REMDACTA), 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Veiga, 2021 8 11% 1,777 moderate not evaluable 0.2 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-03 09:18 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 91
- treatments: 596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526
- roots T: 290
